Severe Marburg virus disease can end in full clinical recovery when early diagnostic identification pairs with prompt antiviral administration and supportive care, according to findings published in the International Journal of Emergency Medicine.
The research details five laboratory-confirmed patients who recovered after receiving care at the Jinka General Hospital Marburg Virus Disease Treatment Center during an epidemic officially announced by the Ethiopian Ministry of Health during late October 2025.
Public health surveillance identified 19 total cases across the regional response, which comprised 14 laboratory-confirmed infections and five probable cases. Nine of the 14 confirmed cases resulted in death, yielding an overall case fatality rate of 64.3 percent. Five patients survived following intensive inpatient management.
Marburg virus is a severe hemorrhagic fever belonging to the Filoviridae family. The pathogen was first identified in 1967 after simultaneous outbreaks in Marburg, Frankfurt, and Belgrade linked to laboratory work with imported African green monkeys from Uganda. Egyptian fruit bats serve as the natural wildlife reservoir for the pathogen, and human infections have historically carried fatality rates spanning from 24 percent up to 90 percent.
Transmission Chains and Initial Presentation
Four of the five survivors examined in the International Journal of Emergency Medicine study contracted the virus through identifiable community and occupational exposure. Three patients were household contacts of known probable or confirmed cases. A fourth patient was a healthcare worker at the Jinka treatment center who had direct occupational contact with confirmed patients and assisted during the delivery-related care of an infected woman while wearing personal protective equipment.
Upon hospital admission, all five patients exhibited classic initial signs of filovirus infection. They presented uniformly with high fever, generalized headache, fatigue, and gastrointestinal complaints like intractable vomiting, watery diarrhea, and abdominal pain. Hematological evaluations demonstrated profound bone marrow suppression and direct hepatocellular injury across the cohort.
Marked leukopenia lowered the white blood cell count to a nadir of 1.55 times 10 to the third power cells per microliter. Severe thrombocytopenia also appeared, with a platelet nadir of 65 times 10 to the third power cells per microliter. Liver injury was apparent through elevated transaminases, with one severely ill individual registering an extreme peak aspartate aminotransferase reading of 1,153 units per liter.
Three Survivors Develop Hemorrhagic Complications
Between days five and seven following the initial appearance of symptoms, three of the five surviving individuals developed explicit bleeding complications. A 15-year-old female suffered three episodes of hematemesis alongside high fever, cough, abdominal pain, and scattered skin lesions. An 18-year-old woman had severe upper gastrointestinal bleeding, while a 35-year-old female caregiver had bloody diarrhea and a history of upper gastrointestinal hemorrhage.
Therapeutic management integrated experimental antiviral therapy alongside aggressive supportive care. Every patient received remdesivir administered intravenously, typically starting with a 200-milligram loading dose followed by daily maintenance doses of 100 milligrams for treatment courses lasting up to ten days. For the 35-year-old patient who developed severe transaminitis, clinicians temporarily suspended remdesivir after five days before safely re-administering it for five additional daily doses following biochemical improvement.
Supportive interventions targeted fluid homeostasis and hemostatic stabilization. Clinical teams administered intravenous crystalloid fluids, intravenous tranexamic acid, vitamin K, fresh-frozen plasma, omeprazole, and metoclopramide. Broad-spectrum empiric antibiotics were given to patients exhibiting profound neutropenia or suspected secondary bacterial infections.
All Five Survivors Achieve Viral Clearance
Serial reverse transcription polymerase chain reaction assays confirmed progressive viral clearance across the cohort. Monitoring of the infected healthcare worker demonstrated a consistent upward trajectory in cycle threshold figures—moving from 20.8 upon admission to 25.4, 29, and eventually 35—which indicated a dropping pathogen load before a first negative molecular assay on day 12 and definitive clearance verification on day 14.
All five survivors achieved viral clearance verified by two consecutive negative tests within a 48-hour window between days 6 and 12 of treatment, and were discharged after hospital stays spanning 10 to 14 days.
Treatment timing appeared to distinguish survivors from non-survivors across the broader regional outbreak. Out of the 14 confirmed cases, ten individuals received remdesivir while four received supportive care alone, and all four patients who did not receive the antiviral agent died.
Among the ten patients who received remdesivir, the five survivors presented early in their clinical illness, whereas five patients who presented at an advanced, delayed stage succumbed despite receiving antiviral therapy.
Frequently Asked Questions About the Jinka Treatment Center Study
What caused the Marburg virus outbreak in southern Ethiopia?
The outbreak was driven by community and household transmission chains involving the filovirus, which maintains a natural wildlife reservoir in the Egyptian fruit bat. The Ethiopian Ministry of Health declared the outbreak in late October 2025.
How many patients survived the outbreak at Jinka General Hospital?
Public health surveillance identified 19 total cases during the response, including 14 laboratory-confirmed infections where nine individuals died and five survived following intensive inpatient management.
What treatment protocols were used for the surviving patients?
Clinicians administered intravenous remdesivir alongside protocolized supportive care, including crystalloid fluid resuscitation, tranexamic acid for hemorrhage, vitamin K, and broad-spectrum antibiotics for secondary infections.
Jinka General Hospital, located in Jinka within the South Ethiopia Regional State, served as the designated Marburg Virus Disease Treatment Center during the 2025 outbreak. The facility coordinated case management with clinical staff from Addis Ababa University and the Federal Ministry of Health, operating as the central referral point for the South Ethiopia Region response that identified 19 total cases across the region.
How long did it take for patients to clear the virus?
Serial molecular testing showed progressive viral clearance, with all five survivors achieving verified viral clearance between days 6 and 12 of treatment before being discharged following hospital stays of 10 to 14 days.